$40.17
0.0% Today
as of Jul 22, 16:56 ET
Last 30 days
Recent Press Releases & News
Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
XOMA Royalty Announces Closing of Its Acquisition by Ligand
Overview
52-week range
$22
$43
87% of range
Avg surprise (last 3)
+204.2%
Avg reaction (last 2)
+5.7%
100% positive
Latest IV / EM
63%
EM ±5.3% · $40 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $0.17 | $0.19 | -10.5% | +183.3% | +0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.70 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $0.48 | $-0.12 | +500.0% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $0.06 | $-0.26 | +123.1% | — | +10.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.59 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.84 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.86 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.60 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.59 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | $0.17 | $0.48 | -64.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | — | $9M | $13M | $16M | — | $7M | $11M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-480,000 | — | $-1M | $5M | $6M | — | $-16M | $-10M |
| Net income | $4M | — | $14M | $9M | $2M | — | $-17M | $16M |
| EPS (diluted) | $0.17 | — | $0.70 | $0.44 | $0.06 | — | $-1.59 | $0.84 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $86M | $83M | $45M | $75M | $90M | $102M | $142M | $144M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $119M | $117M | $111M | $105M | $113M | $126M | $159M | $162M |
| Total assets | $272M | $273M | $263M | $223M | $213M | $221M | $223M | $243M |
| Long-term debt | $89M | $96M | $94M | $102M | $100M | $107M | $108M | $115M |
| Total liabilities | $159M | $169M | $155M | $131M | $128M | $139M | $139M | $143M |
| Total equity | $93M | $84M | $88M | $72M | $85M | $62M | $85M | $100M |